{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:42:32Z","timestamp":1784720552186,"version":"3.55.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"am","delay-in-days":176,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pharmthera.2022.108193","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T02:22:28Z","timestamp":1650939748000},"page":"108193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Clinical advances in oncolytic virotherapy for pediatric brain tumors"],"prefix":"10.1016","volume":"239","author":[{"given":"Gelare","family":"Ghajar-Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Don","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie K.","family":"Totsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Blitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Kachurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Bag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Markert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Bernstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2022.108193_bb0005","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/gt.2011.61","article-title":"Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1","volume":"18","author":"Advani","year":"2011","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0010","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0015","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0020","doi-asserted-by":"crossref","first-page":"i93","DOI":"10.1093\/neuonc\/noy059.294","article-title":"HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN","volume":"20","author":"Ashley","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1089\/hum.2020.101","article-title":"Design and rationale for first-in-human phase 1 immunovirotherapy clinical trial of oncolytic HSV G207 to treat malignant pediatric cerebellar brain tumors","volume":"31","author":"Bernstock","year":"2020","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41417-019-0091-0","article-title":"Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice","volume":"27","author":"Bernstock","year":"2020","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2017.02.001","article-title":"Pre-clinical assessment of C134, a chimeric oncolytic herpes simplex virus, in mice and non-human primates","volume":"5","author":"Cassady","year":"2017","journal-title":"Molecular Therapy - Oncolytics"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0045","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/14712598.2014.915307","article-title":"Adenoviral vector-mediated gene therapy for gliomas: Coming of age","volume":"14","author":"Castro","year":"2014","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0050","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0055","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.omtm.2020.03.028","article-title":"Preclinical toxicology of rQNestin34.5v.2: An oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene","volume":"17","author":"Chiocca","year":"2020","journal-title":"Molecular Therapy, Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.33.8.1395","article-title":"Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir","volume":"33","author":"Coen","year":"1989","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0065","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1038\/mto.2015.15","article-title":"Pediatric cancer gone viral. Part I: Strategies for utilizing oncolytic herpes simplex virus-1 in children","volume":"2","author":"Cripe","year":"2015","journal-title":"Molecular Therapy - Oncolytics"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0075","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter","volume":"103","author":"Dingli","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0092-8674(93)80071-L","article-title":"The human CD46 molecule is a receptor for measles virus (Edmonston strain)","volume":"75","author":"Dorig","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0085","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","article-title":"Response assessment in paediatric high-grade glioma: Recommendations from the response assessment in pediatric neuro-oncology (RAPNO) working group","volume":"21","author":"Erker","year":"2020","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0090","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/35087061","article-title":"Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1","volume":"3","author":"Farassati","year":"2001","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0095","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: A first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Fishelson","year":"2003","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0105","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/mto.2015.16","article-title":"Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in children","volume":"2","author":"Friedman","year":"2015","journal-title":"Molecular Therapy - Oncolytics"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0110","doi-asserted-by":"crossref","first-page":"13930","DOI":"10.1038\/s41598-018-32353-x","article-title":"Enhanced sensitivity of patient-derived pediatric high-grade brain tumor xenografts to oncolytic HSV-1 virotherapy correlates with Nectin-1 expression","volume":"8","author":"Friedman","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0115","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-009-9926-0","article-title":"Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111","volume":"95","author":"Friedman","year":"2009","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/neuonc\/nov123","article-title":"Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses","volume":"18","author":"Friedman","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0130","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0140","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/neuonc\/noab090.190","article-title":"EPCT-04. RESULTS OF A PHASE 1 STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 WITH RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)","volume":"23","author":"Garcia-Moure","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","article-title":"The interleukin-12\/interleukin-12-receptor system: Role in normal and pathologic immune responses","volume":"16","author":"Gately","year":"1998","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0150","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2014.00167","article-title":"Activated ras signaling pathways and reovirus oncolysis: An update on the mechanism of preferential reovirus replication in cancer cells","volume":"4","author":"Gong","year":"2014","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0160","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1073\/pnas.93.6.2370","article-title":"Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants","volume":"93","author":"Gromeier","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41467-020-20469-6","article-title":"Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy","volume":"12","author":"Gromeier","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0170","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1073\/pnas.97.12.6803","article-title":"Intergeneric poliovirus recombinants for the treatment of malignant glioma","volume":"97","author":"Gromeier","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0175","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/1471-2407-12-508","article-title":"Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine","volume":"12","author":"Hutzen","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0180","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/mt.2014.118","article-title":"Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus","volume":"22","author":"Ilett","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0185","article-title":"THER-09. Oncolytic adenovirus, DNX-2401, for naive diffuse intrinsic pontine gliomas: A phase 1 clinical trial","volume":"22","author":"I\u00f1igo-Marco","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0190","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/neuonc\/now038","article-title":"Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: A report of the children\u2019s oncology group ACNS0423 study","volume":"18","author":"Jakacki","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0195","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3811","article-title":"Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma","volume":"14","author":"Jones","year":"2014","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-016-0116-2","article-title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","volume":"4","author":"Kaufman","year":"2016","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0210","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Kicielinski","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/OV.S196403","article-title":"Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma","volume":"8","author":"Kiyokawa","year":"2019","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-017-2701-8","article-title":"Survival outcomes in pediatric recurrent high-grade glioma: Results of a 20-year systematic review and meta-analysis","volume":"137","author":"Kline","year":"2018","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0225","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/pbc.25464","article-title":"A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children\u2019s oncology group phase I consortium report","volume":"62","author":"Kolb","year":"2015","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0230","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.virol.2004.02.005","article-title":"Comparative usage of herpesvirus entry mediator a and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus","volume":"322","author":"Krummenacher","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0235","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Therapy"},{"issue":"520\u2013537","key":"10.1016\/j.pharmthera.2022.108193_bb0245","article-title":"Integrated molecular Meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0250","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/sj.cgt.7700940","article-title":"Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus ad-Delta24RGD","volume":"13","author":"Majem","year":"2006","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0255","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0260","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0265","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0270","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Martinez-Velez","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0275","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0280","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/S1152851703000577","article-title":"Poliovirus receptor CD155-targeted oncolysis of glioma","volume":"6","author":"Merrill","year":"2004","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0285","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-05-1927","article-title":"Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses","volume":"65","author":"Mezhir","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0290","article-title":"Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant","volume":"54","author":"Mineta","year":"1994","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0295","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113219","article-title":"Past, present and future of oncolytic reovirus","volume":"12","author":"Muller","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0305","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: A report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0310","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O\u2019Shea","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0315","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0320","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent\/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Human Gene Therapy. Clinical Development"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0325","first-page":"4656","article-title":"Intraperitoneal therapy of ovarian cancer using an engineered measles virus","volume":"62","author":"Peng","year":"2002","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100777","article-title":"Pediatric brain tumors: The era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae","volume":"45","author":"Plant-Fox","year":"2021","journal-title":"Current Problems in Cancer"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0335","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-07-1510","article-title":"Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus","volume":"14","author":"Qiao","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0340","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.gt.3301184","article-title":"Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma","volume":"7","author":"Rampling","year":"2000","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0345","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0350","first-page":"1","article-title":"Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma","author":"Shimizu","year":"2021","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0355","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0360","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0365","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/neuonc\/nor231","article-title":"Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma","volume":"14","author":"Studebaker","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0370","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/neuonc\/nov058","article-title":"Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors","volume":"17","author":"Studebaker","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.omto.2017.05.005","article-title":"Oncolytic herpes virus rRp450 shows efficacy in orthotopic xenograft group 3\/4 medulloblastomas and atypical teratoid\/rhabdoid tumors","volume":"6","author":"Studebaker","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0380","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noq057","article-title":"Treatment of medulloblastoma with a modified measles virus","volume":"12","author":"Studebaker","year":"2010","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0385","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2457","article-title":"Nectins and nectin-like molecules: Roles in contact inhibition of cell movement and proliferation","volume":"9","author":"Takai","year":"2008","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0390","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/neuros\/nyx507","article-title":"Phase I trial of DNX-2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients","volume":"83","author":"Tejada","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0395","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fonc.2018.00061","article-title":"DNX-2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas: A case report","volume":"8","author":"Tejada","year":"2018","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0400","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jnen\/nly045","article-title":"Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma","volume":"77","author":"Thompson","year":"2018","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0405","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0410","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/hum.2007.002","article-title":"Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma","volume":"18","author":"Ulasov","year":"2007","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0415","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0420","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nbt887","article-title":"E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models","volume":"21","author":"Wang","year":"2003","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0425","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/humc.2017.002","article-title":"Rationale and design of a phase 1 clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant supratentorial brain tumors","volume":"28","author":"Waters","year":"2017","journal-title":"Human Gene Therapy. Clinical Development"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0430","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/hum.2010.129","article-title":"Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2\/1, 2\/2, 2\/rh8, 2\/9, and 2\/rh10) by convection-enhanced delivery to the striatum","volume":"22","author":"White","year":"2011","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0435","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jgm.1567","article-title":"An evaluation of site-specific immune responses directed against first-generation adenoviral vectors administered by convection-enhanced delivery","volume":"13","author":"White","year":"2011","journal-title":"The Journal of Gene Medicine"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0440","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1172\/JCI116527","article-title":"Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models","volume":"91","author":"Whitley","year":"1993","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0445","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(89)90984-7","article-title":"Cellular targets for transformation by the adenovirus E1A proteins","volume":"56","author":"Whyte","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108193_bb0450","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12935-021-01972-2","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell International"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:23:47Z","timestamp":1759011827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":90,"alternative-id":["S0163725822000870"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108193","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical advances in oncolytic virotherapy for pediatric brain tumors","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108193"}}